Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 11, 2020

View Archived Issues

Antigen agnostic tolerizing therapy in MS

Small-molecule compound targets amyloid beta

FDA places IND on hold for PRAX-114 in major depressive disorder

BRKB-28 shows promising in vitro efficacy in breast and gastric cancer

Phase I data reported for Medicago's COVID-19 vaccine candidate

Preliminary phase I data for AT-301 nasal spray being developed for COVID-19

Ariagen patents AhR agonists for cancer

Janssen Pharmaceutica discloses BARK1 inhibitors

Colorado Research Partners identifies KHK inhibitors

NiKang Therapeutics synthesizes new HIF-2alpha inhibitors

New oncolytic adenoviral vectors presented by Targovax

SHR-0302 displays dose-dependent effects in rheumatoid arthritis

First-in-human data for LNA-043 as treatment of knee osteoarthritis

Rallybio begins phase I/II study of RLYB-211 for fetal and neonatal alloimmune thrombocytopenia

Phase II trial of bemarituzumab in gastric or GEJ cancer meets primary endpoints

Promising phase II data for deucravacitinib in active psoriatic arthritis

[64Cu]DOTA-UBI 29-41 for imaging of active infectious processes

First phase IIa data presented on AR-882, a potent and selective uricosuric drug

Small molecule targets same repeat expansion in distinct diseases

Corbus reports post-hoc analyses of RESOLVE-1 study of lenabasum for systemic sclerosis

Ono initiates phase III study of Foipan for COVID-19

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...